Regencell Bioscience Holdings Ltd
StreetZero Signal 56
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It targets treatments for neurocognitive disorders and degenerative diseases. The company is publicly traded on NASDAQ under ticker RGC following its 2021 IPO. It reports zero revenue and ongoing operating losses.
LATEST FUNDINGRule 144
$170K
Announced 2026-11-17
IN THE NEWS
- ๐ Regencell Bioscience
- ๐ Regencell Bioscience Holdings Limited
- ๐ Regencell Bioscience Holdings Limited (RGC) Stock Price, News, Quote & History - Yahoo Finance
- ๐ Regencell Bioscience Holdings Share Price Today | NASDAQ RGC Stock - Investing.com AU
- ๐ Regencell Bioscience Holdings Ltd Stock Price Today | NASDAQ: RGC Live - Investing.com
EMPLOYEESโ
FOUNDED2014
HQCauseway Bay, Hong Kong
Industry
Public Equity (Nasdaq)
Tags
BiotechnologyTraditional Chinese MedicinePublic CompanyHealthcare
Investors
Not disclosed in the source filing. Form D filings do not list investors โ StreetZero surfaces them from news where available.
Key highlights
- Publicly traded on NASDAQ:RGC since July 2021 IPO
- Develops TCM therapies for neurocognitive and degenerative conditions
- Reports zero annual revenue and negative EBITDA of approximately -11.6M USD
- Headquartered in Hong Kong with market cap near 94M USD as of late 2024
Ask StreetZero about Regencell Bioscience Holdings Ltd
Put our AI to work on this deal.
Similar companies
Other Public Equity (Nasdaq) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account